Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

Cassava Sciences’ stock (NASDAQ: SAVA) plummeted on Monday by a staggering 85%. “The results are disappointing for patients and their families who are living with this disease and physicians ...

Investment Overview. The share price of Cassava Sciences (NASDAQ:SAVA) increased from ~$1, to $10 between 2019 and 2020, tread water between 2020 and 2021, had increased in value to >$120 by ...

Get the latest news on Cassava Sciences stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SAVA performance ...

Shares of Cassava Sciences (SAVA 2.83%) skyrocketed in the first half of 2021. The biotech's share price ran up 1,152% from the first of January to the end of June.

After surging from $7 per share to around $120 per share this year, Cassava Sciences (NASDAQ:SAVA) stock may not have room to make more “to the moon” moves higher. Source: Atthapon Raksthaput ...

Investing in Cassava Sciences (NASDAQ:SAVA) makes sense based on its fundamental financial position, but it remains a gamble. The company has run up against serious allegations in pursuit of Food ...

Review Cassava Sciences Inc (SAVA:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

The market's been in love with Cassava Sciences (SAVA 2.83%) all year, but it's definitely a rocky relationship. The stock soared from $8 a share back in January to $126 on Aug. 12.